SMS at the total study period
In ILIT after SCIT-10 000, the daily symptom scores (SS) did not change
when comparing the scores before versus after treatment. In contrast,
the medication use was significantly lowered in the active group the
year after treatment, measured as a 52% reduction of the median
medication scores (MS). The placebo group did not change.
(See Figure 3 and Table 3.) When
comparing the active versus the placebo group, the SS was unbalanced at
baseline with 41% lower scores in the placebo group than in the active
group (p=0.02, see Table 1). After treatment, the gap between the groups
had narrowed and there was no significant difference. The placebo group
(n=11) had median SS 21.8 (IQR 13.1-32.6) and the active group (n=13)
had median SS 43.7 (IQR 13.4-53.2), p=0.31. The MS was balanced at
baseline and the result of the between group comparison had not changed
after treatment. The placebo group (n=11) had median MS 28.0 (IQR
6.5-33.5) after treatment, and the active group (n=13) had median MS
27.5 (IQR 3.0-63.3) after treatment, p=0.91.
In ILIT de novo- 3000, the SS and MS were lower in both the active and
placebo group the year after treatment. The SS was reduced by 25% in
active group and 20% in the placebo group. MS was reduced by 32% in
active group and 36% in the placebo group. (See Figure 3 and Table 3.)
Analysis between the active (n=16) and placebo group (n=18) after
treatment did not reveal any differences in SS (p= 0.49) or MS (p=0.64).
(See Table 3.)